ArticleScience immunology2024
Immunization with germ line-targeting SOSIP trimers elicits broadly neutralizing antibody precursors in infant macaques.
Abstract read
In one paragraph
Article in Science immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Precise targeting of HIV broadly neutralizing antibody precursors in humans.Science (New York, N.Y.) · 2025Trial
- Learned young: HIV-1 germline-targeting vaccination in infants.Current opinion in HIV and AIDS · 2026Review
- What's Hot in HIV in 2025-A Basic and Translational Science Review From IDWeek 2025.The Journal of infectious diseases · 2026Review
- Antibody-mediated targeting of SOSIP HIV-1 Env to skin Langerhans cells potentiates humoral responses.EBioMedicine · 2026Article
- Immunomodulation by glycosylation: bridging glycobiology to adaptive immunity and therapeutic innovation.Frontiers in immunology · 2026Review
- Integration of Preclinical and Clinical Vaccine Safety and Immunogenicity Testing for Development of a Pediatric HIV Vaccine to Achieve Protective HIV Immunity Prior to Adolescence.Current HIV research · 2026Review
- Parallel evolution of the elite neutralizer phenotype in divergent HIV-1 clades.Journal of virology · 2025Article
- A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimers.Journal of virology · 2025Article
- Evolving rare B cell lineages for an effective HIV vaccine.Science (New York, N.Y.) · 2025Article
- Optimizing human B cell repertoire analyses to interpret clinical data and design sequential HIV vaccines.NPJ vaccines · 2025Article
- Transient glycan shield reduction induces CD4-binding site broadly neutralizing antibodies in SHIV-infected macaques.Cell reports · 2025Article
- Antibody function predicts viral control in newborn monkeys immunised with an influenza virus HA stem nanoparticle.Nature communications · 2025Article
- Navigating the Complexities of HIV Vaccine Development: Lessons from the Mosaico Trial and Next-Generation Development Strategies.Vaccines · 2025Article
- HIV: how close are we to a vaccine - or a cure?Nature · 2024Article
- Nonhuman primate models of pediatric viral diseases.Frontiers in cellular and infection microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
42 authors.
Ashley N NelsonDepartment of Pediatrics, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-4647-7667
Xiaoying ShenHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-8387-3952
Sravani VekatayogiHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0001-8976-6827
Shiyu ZhangDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0003-4586-0605
Gabriel OzorowskiDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-9695-8138
Maria DennisDepartment of Pediatrics, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-0833-2635
Leigh M SewallDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0002-2020-2991
Emma MilliganDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-5062-6253
Dominique DavisDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kaitlyn A CrossGillings School of Public Health and Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-6455-9220
Yue ChenHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-4977-8724
Jelle van SchootenDepartment of Medical Microbiology, Academic Medical Center, Amsterdam, Netherlands.ORCID 0000-0002-5202-355X
Joshua EudaileyDepartment of Pediatrics, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-1731-9806
John IsaacDepartment of Pediatrics, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-1133-7955
Saad MemonDepartment of Pediatrics, Weill Cornell Medicine, New York, NY, USA.ORCID 0009-0002-2460-0679
Carolyn WeinbaumDepartment of Pediatrics, Weill Cornell Medicine, New York, NY, USA.ORCID 0009-0006-8009-8010
Hongmei GaoHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-2468-8589
Sherry Stanfield-OakleyHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-6347-1956
Alliyah ByrdHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
Suni ChutkanHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
Stella BerendamHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0001-9622-2238
Kenneth CroninHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-5984-5978
Anila YasmeenDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-2386-8991
S AlamHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0003-0941-0703
Celia C LaBrancheHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-6653-6655
Kenneth RogersNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.ORCID 0000-0002-3911-035X
Lisa ShirreffNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.ORCID 0000-0002-8403-451X
Albert CupoDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0001-7579-3525
Ronald DerkingDepartment of Medical Microbiology, Academic Medical Center, Amsterdam, Netherlands.
Francois VillingerNew Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, USA.ORCID 0000-0002-7790-2008
Per Johan KlasseDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0001-8222-278X
Guido FerrariHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0001-7747-3349
Wilton B WilliamsHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0002-2970-7259
Michael G HudgensGillings School of Public Health and Center for AIDS Research, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-9106-4194
Andrew B WardDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA, USA.ORCID 0000-0001-7153-3769
David C MontefioriHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0003-0856-6319
Koen K A Van RompayCalifornia National Primate Research Center, University of California, Davis, CA, USA.ORCID 0000-0002-7375-1337
Kevin WieheHuman Vaccine Institute, Duke University Medical Center, Durham, NC, USA.ORCID 0000-0001-9933-9618
John P MooreDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-9902-6096
Rogier W SandersDepartment of Medical Microbiology, Academic Medical Center, Amsterdam, Netherlands.ORCID 0000-0002-2324-8573
Kristina De ParisDepartment of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-5199-3004
Sallie R PermarDepartment of Pediatrics, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-1438-4554
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MNational Institute on Aging (NIA) ColonyP51OD011107 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Simon J. Atkinson · 2012 to 2026
$191.5MVirology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9MStructural studies of native-like SOSIP trimersP01AI110657 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI MOORE, JOHN P · 2015 to 2024
$35.4MBiostatstics for Research in Environmental HealthT32ES007018 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Stephanie Engel, Rebecca Fry · 1985 to 2026
$31.3MProject 2: RNA vaccination in early life to induce potent and broad HIV Env-specific antibody responsesP01AI117915 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI DE PARIS, KRISTINA, PERMAR, SALLIE R. · 2015 to 2024
$21.2MInstitutional Career Development CoreKL2TR002385 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI YUAN-SHAN ZHU · 2017 to 2026
$13.3MNCATS NIH HHS KL2 TR002385NCI NIH HHS P30 CA016086NIAID NIH HHS HHSN272201800004CNIAID NIH HHS P01 AI110657NIAID NIH HHS P01 AI117915NIAID NIH HHS P30 AI050410NIEHS NIH HHS T32 ES007018NIH HHS P51 OD011107
Abstract
Adolescents are a growing population of people living with HIV. The period between weaning and sexual debut presents a low-risk window for HIV acquisition, making early childhood an ideal time for implementing an immunization regimen. Because the elicitation of broadly neutralizing antibodies (bnAbs) is critical for an effective HIV vaccine, our goal was to assess the ability of a bnAb B cell lineage-designed HIV envelope SOSIP (protein stabilized by a disulfide bond between gp120-gp41-named "SOS"-and an isoleucine-to-proline point mutation-named "IP"-at residue 559) to induce precursor CD4 binding site (CD4bs)-targeting bnAbs in early life. Infant rhesus macaques received either a BG505 SOSIP, based on the infant BG505 transmitted/founder virus, or the CD4bs germ line-targeting BG505 SOSIP GT1.1 (
Indexed as
AIDS VaccinesHIV AntibodiesMacaca mulattaAnimalsAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusGerm CellsHIV-1HIV InfectionsHumansImmunizationAIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.